Pauline Brice

TL;DR: Chen et al. as mentioned in this paper evaluated pembrolizumab in patients with R/R cHL that progressed after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) therapy.

TL;DR: QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints, and with few exceptions, mean improvements from baseline to weeks 12 and 24 in QLZC30 functional and symptom scores occurred in all cohorts.

TL;DR: This phase II study represents one of the largest prospectively designed trials in relapsed/refractory ALCL and demonstrates good tolerability and clinically meaningful antitumor activity of SGN-30, especially in ALK negative patients who have a particularly poor prognosis.

TL;DR: High dose total or subtotal nodal irradiation following four courses of chemotherapy was feasible, although hematological toxicity grade > or = 2 (World Health Organization) was observed in one-third of the patients, particularly in patients aged over 40.

TL;DR: It is suggested that radiotherapy may be useful as a consolidation modality in PB-DLBCL and positron emission tomography/CT scan should be interpreted with caution due to a persistent [18F]fluorodeoxyglucose [18FDG] uptake of bone lesions even after remission in some patients.